In diabetic animal models, the amelioration of mitochondrial function due to GLP1-RA administration led to a significant reduction in collagen deposition, improving cardiac remodeling, diastolic function and the incidence of AF [29] However, a meta-analysis showed no significant reduction in the risk of major arrhythmias in more than 60,000 diabetic patients treated with GLP1-RA, including AF (relative risk (RR) = 0.96, 95% confidential interval (CI) (0.86, 1.07), p = 0.43) [27], and a French cohort study showed an increased risk of AF in patients treated with GLP1-RA [32]. Here, GLP1R is linked to atrial fibrillation.